Drugs / IMISOPASEM MANGANESE
IMISOPASEM MANGANESE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00033956 | Dec 2001 → ? | orthostatic hypotension 2 | MetaPhore Pharmaceuticals | Suspended | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00101621 | Aug 2004 → Aug 2005 | cancer | MetaPhore Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMISOPASEM MANGANESE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544979 ↗ |
| Known as | GC-4403 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544979 ↗ |
| Known as | Imisopasem manganese dichloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544979 ↗ |
| Known as | Imisopasem manganeso | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544979 ↗ |
| Known as | M40403 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00101621 ↗ |
| Known as | SC-72325 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544979 ↗ |
| Modality | Small molecule | — CHEMBL3544979 ↗ |
| Route | Intravenous | “M40403 will be administered by intravenous infusion over 30 minutes prior to each intravenous administration of high dose IL-2.” NCT00033956 ↗ |